» Articles » PMID: 12435687

In Vitro Activity of Micafungin (FK-463) Against Candida Spp.: Microdilution, Time-kill, and Postantifungal-effect Studies

Overview
Specialty Pharmacology
Date 2002 Nov 19
PMID 12435687
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated the in vitro activity of the new echinocandin antifungal micafungin against Candida spp. using microdilution and time-kill methods. Additionally, we examined the postantifungal effect (PAFE) of micafungin. Finally, we evaluated the effect of the addition of serum and plasma on the MIC of micafungin. Four Candida albicans isolates and two isolates of each Candida glabrata, Candida krusei, and Candida tropicalis were selected for testing. The MICs of micafungin were determined in RPMI 1640 medium buffered with morpholinepropanesulfonic acid alone and with the addition of 10, 20, and 50% human serum and plasma. MICs were determined by using two endpoints: a prominent reduction in growth (the MIC at which 80% of isolates are inhibited [MIC(80)]) and complete visual inhibition of growth (MIC(100)). The minimum fungicidal concentration (MFC) of micafungin for each isolate was also determined. Time-kill curves were determined for each isolate in RPMI 1640 medium with micafungin at concentrations ranging from 0.125 to 16 times the MIC(80) to assess the correlation between MIC(80) and fungicidal activity. PAFE studies were conducted with each isolate by using concentrations ranging between 0.25 and 4 times the MIC(80). The MIC(80)s for the test isolates ranged from 0.0039 to 0.25 micro g/ml. Overall, the addition of serum or plasma increased the MIC 6 to 7 doubling dilutions for C. albicans and 3 to 4 doubling dilutions for C. krusei and C. tropicalis. Micafungin time-kill studies demonstrated fungicidal activity at concentrations ranging from 4 to 16 times the MIC(80). Micafungin is very potent agent against a variety of Candida spp., producing fungicidal activity against 7 of 10 isolates tested. A PAFE was observed against all isolates. The PAFE was influenced by the drug concentration, with the highest concentration resulting in the longest observed PAFE in each case. The highest concentration tested, four times the MIC, resulted in a PAFE of more than 9.8 h for 5 of 10 isolates tested (range, 0.9 to > or =20.1 h).

Citing Articles

Ellagic Acid Potentiates the Inhibitory Effects of Fluconazole Against .

Mendes A, Campos C, Pereira-Filho J, Pereira A, Reis G, Araujo A Antibiotics (Basel). 2025; 13(12.

PMID: 39766564 PMC: 11672414. DOI: 10.3390/antibiotics13121174.


Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by and in Neutropenic Rabbit Models.

Petraitiene R, Petraitis V, Zaw M, Hussain K, Ricart Arbona R, Roilides E J Fungi (Basel). 2024; 10(4).

PMID: 38667964 PMC: 11050883. DOI: 10.3390/jof10040293.


Synergistic potential of teriflunomide with fluconazole against resistant and .

Li X, Kong B, Sun Y, Sun F, Yang H, Zheng S Front Cell Infect Microbiol. 2024; 13:1282320.

PMID: 38169891 PMC: 10758495. DOI: 10.3389/fcimb.2023.1282320.


In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in spp.

Franconi I, Lupetti A J Fungi (Basel). 2023; 9(12).

PMID: 38132789 PMC: 10744879. DOI: 10.3390/jof9121188.


Postantifungal Effect of Antifungal Drugs against : What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?.

Jauregizar N, Quindos G, Gil-Alonso S, Suarez E, Sevillano E, Eraso E J Fungi (Basel). 2022; 8(7).

PMID: 35887482 PMC: 9317160. DOI: 10.3390/jof8070727.


References
1.
Klepser M, Ernst E, Lewis R, Ernst M, Pfaller M . Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother. 1998; 42(5):1207-12. PMC: 105779. DOI: 10.1128/AAC.42.5.1207. View

2.
Ernst E, Klepser M, Ernst M, Messer S, Pfaller M . In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis. 1999; 33(2):75-80. DOI: 10.1016/s0732-8893(98)00130-8. View

3.
Klepser M, Wolfe E, Jones R, Nightingale C, Pfaller M . Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother. 1997; 41(6):1392-5. PMC: 163923. DOI: 10.1128/AAC.41.6.1392. View

4.
Ernst E, Klepser M, Pfaller M . Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(4):1108-11. PMC: 89826. DOI: 10.1128/AAC.44.4.1108-1111.2000. View

5.
Zhanel G, Saunders D, Hoban D, Karlowsky J . Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother. 2001; 45(7):2018-22. PMC: 90594. DOI: 10.1128/AAC.45.7.2018-2022.2001. View